Recursion Pharmaceuticals Inc (RXRX)

Currency in USD
3.75
+0.21(+5.93%)
Closed·
3.74-0.01(-0.27%)
·

Recursion Pharmaceuticals Inc Company Profile

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Contact Information

Address
41 South Rio Grande Street, Salt Lake City, 84101, United States
Phone
385 269 0203

Top Executives

Name
Title
Since
Age
Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor202643
Najat KhanCEO, President & Director202641
Robert M. HershbergVice-Chairman & Lead Independent Director202664
Zavain DarIndependent Director201637
Joseph P. MiletichChairman of Therapeutics Advisory Board202174
Elaine D. SunIndependent Director202553
Anne CarpenterMember of Scientific and Technical Advisory Board2014-
Kirk R. ThomasMember of Scientific & Technical Advisory Board2014-
Dean Y. LiDirector202663
Blake C. BorgesonIndependent Director201344
H. Perry FellMember of Business Advisory Panel201469
Robert J. LolliniMember of Business Advisory Panel201472
Zachary S. BogueIndependent Director201851
Franziska MichorIndependent Director202444
Namandje N. BumpusIndependent Director202544
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.